Immuno-oncologyVideos + subtitles + PDFs2026
MSKCC Foundations in Immunotherapy in the Oncology Population 2026 — checkpoints, CAR T and bispecifics made practical
MSKCC Foundations in Immunotherapy in the Oncology Population 2026 records Memorial Sloan Kettering’s virtual course of Wednesday 28 January 2026 as 23 MP4 videos, 23 VTT subtitle files and 20 PDFs (4.97 GB). It begins with how PD-1, PD-L1 and CTLA-4 blockade and CAR T cells actually work, applies them disease by disease from Hodgkin lymphoma to synovial sarcoma, and finishes with the toxicities clinicians meet at the bedside: pneumonitis, skin reactions, CRS, ICANS and prolonged cytopenias.
- 23videos
- 20PDFs
- 4.97 GBdownload
- 5Q&A sessions
What you’ll be able to do
- Explain the mechanism of checkpoint blockade and of chimeric antigen receptor T cells
- Match immunotherapy options to tumour type, from bladder and small cell lung cancer to myeloma
- Recognise and grade immune-related pneumonitis and dermatologic toxicity
- Manage CRS, ICANS and prolonged cytopenias after cell therapy
- Follow the evidence on dostarlimab in MSI-high GI cancers and cfDNA response prediction in breast cancer
Inside the course
MSKCC Foundations in Immunotherapy: the biology
Opening talks explain checkpoint mechanisms, CAR T construction and IL-2-stimulating agents emerging from early drug development, then review novel checkpoint inhibitors and combinations.
Solid tumours
Melanoma subtypes as a model for checkpoint efficacy, advanced bladder cancer, DLL3 agents and adjuvant durvalumab in small cell lung cancer, MSI-high GI tumours, gynaecologic CAR T strategies and T-cell therapy for synovial sarcoma.
Haematologic malignancies
Checkpoint inhibition in advanced Hodgkin lymphoma, immuno-oncology in leukaemia and bispecific agents for multiple myeloma show where immune therapy now sits in blood cancer care.
Toxicity at the bedside
Dedicated sessions on pneumonitis, skin toxicity, cell-therapy adverse events and CAR T neurotoxicity turn guidelines into algorithms, with five Q&A discussions spread across the day.
Built for
- Medical and haematologic oncologistsA compact refresher across solid and liquid tumours.
- Oncology nurses, NPs and PAsToxicity recognition and escalation are covered in detail.
- Hospitalists and pulmonologistsPneumonitis and CRS sessions help with patients admitted on immunotherapy.
Faculty & syllabus
Sessions (alphabetical) 24 sessions
- Advancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies
- Advancing Leukemia Care Through Immuno-Oncology
- Approaches to Immunotherapy-related Pneumonitis Management
- Breast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes
- Checkpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma
- Clinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy
- Discussion of Novel Checkpoint Inhibitors and Combination Therapy
- Dostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights
- Evolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer
- IL-2-Stimulating Agents from Early Drug Development
- Innovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab
- Intrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease (no video)
- Mechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4
- Melanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology
- Neurotoxicity in CAR T-Cell Therapy- Recognition and Management
- Overview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias
- Q&A and Discussion – 01
- Q&A and Discussion – 02
- Q&A and Discussion – 03
- Q&A and Discussion – 04
- Q&A and Discussion
- Targeting Multiple Myeloma with Bispecific Immune-Modulating Agents
- The Role of T-Cell Therapy in Standard Care for Synovial Sarcoma
- Understanding Chimeric Antigen Receptor (CAR) T-Cell Therapy
Before you buy
Is every talk on video?
All but one: the intrathecal immunotherapy talk on leptomeningeal disease has no video recording. There are also fewer PDFs (20) than videos, so a few sessions lack handouts.
Are speaker names listed?
No, only session titles were supplied for this course.
Do I get CME credit or a certificate?
No. Clinicapedia provides the educational content only — no CME or CE credits, MOC points or certificates of completion are included with this product.
Specifications
| Format | MP4 videos · VTT subtitles · PDFs |
|---|---|
| Contents | 23 videos · 23 subtitle files · 20 PDFs |
| Size | 4.97 GB |
| Course date | 28 January 2026 (online) |
| Publisher | Memorial Sloan Kettering Cancer Center |
| Department | Oncology |
| Delivery | Instant download · lifetime re-download |
Related products
Harvard Medicine
Oncology-Hematology
Cleveland Clinic Basic & Clinical Immunology for the Busy Clinician 2025
Cardiology
Anesthesiology
Oncology-Hematology